Sermion® (Nicergoline) Instruction
International Non-Proprietary Name (INN): nicergoline
Dosage form: tablets
In 1 tablet:
Active ingredient: nicergoline 5 mg;
Excipients: calcium hydrogen phosphate dihydrate – 100 mg, MCC – 22.4 mg, magnesium stearate – 1.3 mg, sodium carboxymethyl cellulose – 1.3 mg.
Tablets: round, convex, coated with an orange shell.
Pharmacological classification: α-adrenoblocker (corrector of cerebrovascular disorders)
ATC code: C04AE02
Pharmacological action: α-adrenoblocker (corrector of cerebrovascular disorders)
The drug improves cerebral and peripheral blood circulation; it has α-adrenoblocking and metabolism activating action.
It reduces vascular resistance, increases arterial blood flow and the consumption of oxygen and glucose by brain tissues. It lowers pulmonary vascular resistance. The drug reduces platelet aggregation and improves hemorheological parameters.
It increases blood flow speed in the vessels of the upper and lower extremities, especially in case of impaired blood flow because of functional arteriopathy. Clinical trials have shown the high efficiency of Sermion® in case of cerebrovascular disorder and arterial blood flow insufficiency in the vessels of the upper and lower extremities.
Sermion® administration in therapeutic doses does not usually affect blood pressure. In patients with arterial hypertension, the drug can cause a gradual decrease in blood pressure.
Studies of the pharmacokinetics of Sermion® have not been conducted.
- cerebral atherosclerosis;
- thrombosis and embolism of cerebral vessels;
- transient cerebrovascular disorders of the ischemic type;
- obliterating endarteritis;
- Raynaud syndrome;
- hypertensive crisis (parenteral administration of the drug as an adjuvant);
- arterial hypertension (as part of combination therapy).
Hypersensitivity to the drug.
Dosage and administration
Per os, the drug is prescribed in the dosage of 5–10 mg 3 times/day with the same intervals between the intakes for a long period. To improve absorption, the drug should be taken between meals.
In some cases, it is advisable to begin the treatment with the parenteral administration of the drug (Sermion® powder lyophilisate for injections, 4 mg per vial, 4 ml [with solvent] per ampule, 4 in a pack, Pfizer) with subsequent transition to oral administration during the maintenance therapy.
For the easy dosage, you can use Sermion® drug in coated tab. 5 mg 30 in a pack, Pfizer.
The cardiovascular system
Rarely: Fever sensation and face flushing.
The central nervous system
Rarely: Drowsiness, insomnia.
The digestive system
Rarely: Mild gastric disorders.
No case of overdose has been described yet.
Interaction with other drugs
In the case of simultaneous administration, Sermion® can potentiate the effect of antihypertensive drugs.
Pregnancy and lactation
During pregnancy, the drug is prescribed only in case of compelling medical reasons. No teratogenic effect of nicergoline has been revealed in experimental studies.
Sermion® helps to improve concentration. The effect of the drug on the ability to drive vehicles and to work with mechanisms has never been studied. Nevertheless, taking into account the disease for which the drug is prescribed, it is recommended to exercise caution when driving or working with mechanisms.
Terms of release from pharmacy
Store in a dry dark place at temperatures no higher than 30°C. Keep out of reach of children.
3 years. Do not use beyond the expiration date printed on the package.
Pfizer, USA / Italy. https://www.pfizer.com/